8.37
price down icon4.67%   -0.41
 
loading
Schlusskurs vom Vortag:
$8.78
Offen:
$8.75
24-Stunden-Volumen:
9.96M
Relative Volume:
1.19
Marktkapitalisierung:
$1.36B
Einnahmen:
$847.25M
Nettoeinkommen (Verlust:
$-284.86M
KGV:
-3.655
EPS:
-2.29
Netto-Cashflow:
$-112.35M
1W Leistung:
+27.59%
1M Leistung:
+18.89%
6M Leistung:
+2.95%
1J Leistung:
-28.34%
1-Tages-Spanne:
Value
$8.28
$9.1278
1-Wochen-Bereich:
Value
$6.545
$9.1278
52-Wochen-Spanne:
Value
$5.01
$15.22

Novavax Inc Stock (NVAX) Company Profile

Name
Firmenname
Novavax Inc
Name
Telefon
240-268-2000
Name
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Name
Mitarbeiter
1,992
Name
Twitter
@novavax
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
NVAX's Discussions on Twitter

Vergleichen Sie NVAX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NVAX
Novavax Inc
8.37 1.23B 847.25M -284.86M -112.35M -2.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Novavax Inc Stock (NVAX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-17 Eingeleitet Citigroup Sell
2025-02-28 Eingeleitet BTIG Research Buy
2024-07-30 Herabstufung JP Morgan Neutral → Underweight
2024-05-10 Hochstufung BofA Securities Underperform → Neutral
2024-05-10 Hochstufung JP Morgan Underweight → Neutral
2023-08-09 Hochstufung B. Riley Securities Neutral → Buy
2023-04-20 Herabstufung TD Cowen Outperform → Market Perform
2023-03-01 Herabstufung B. Riley Securities Buy → Neutral
2023-01-09 Bestätigt B. Riley Securities Buy
2022-12-30 Bestätigt H.C. Wainwright Buy
2022-12-02 Eingeleitet Jefferies Hold
2022-09-22 Herabstufung JP Morgan Neutral → Underweight
2022-05-20 Eingeleitet BofA Securities Underperform
2022-02-23 Bestätigt B. Riley Securities Buy
2022-02-22 Fortgesetzt Jefferies Buy
2022-01-21 Eingeleitet Cowen Outperform
2021-05-12 Herabstufung JP Morgan Overweight → Neutral
2020-12-14 Eingeleitet Jefferies Buy
2020-08-06 Bestätigt H.C. Wainwright Buy
2020-08-05 Hochstufung JP Morgan Neutral → Overweight
2020-08-05 Herabstufung Ladenburg Thalmann Neutral → Sell
2020-07-16 Bestätigt H.C. Wainwright Buy
2020-07-08 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-06-29 Bestätigt B. Riley FBR Buy
2020-06-29 Bestätigt H.C. Wainwright Buy
2020-06-05 Hochstufung JP Morgan Underweight → Neutral
2020-05-28 Bestätigt B. Riley FBR Buy
2020-05-12 Bestätigt H.C. Wainwright Buy
2020-04-30 Bestätigt H.C. Wainwright Buy
2019-11-27 Fortgesetzt B. Riley FBR Buy
2019-08-14 Bestätigt H.C. Wainwright Buy
2019-02-28 Herabstufung Piper Jaffray Overweight → Underweight
2018-12-18 Eingeleitet Ladenburg Thalmann Buy
2018-12-11 Eingeleitet Oppenheimer Outperform
2018-11-26 Hochstufung Piper Jaffray Neutral → Overweight
2018-09-21 Hochstufung JP Morgan Underweight → Overweight
2018-03-29 Hochstufung Seaport Global Securities Neutral → Buy
Alle ansehen

Novavax Inc Aktie (NVAX) Neueste Nachrichten

pulisher
Aug 07, 2025

Novavax’s Q2 Financial Success: A Game Changer? - StocksToTrade

Aug 07, 2025
pulisher
Aug 07, 2025

NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 07, 2025
pulisher
Aug 07, 2025

Novavax Reports Strong Earnings Amid Strategic Shifts - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Novavax: Q2 Earnings Snapshot - Connecticut Post

Aug 07, 2025
pulisher
Aug 06, 2025

Novavax Q2 2025 Earnings Call Transcript - MarketBeat

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax (NVAX) Profit Jumps on Milestone - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax raises 2025 revenue target to $1.05B with milestone payments and streamlined expenses as Sanofi partnership progresses - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax (NVAX) Reports Q2 Progress and Key Partnership Developme - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Transcript : Novavax, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax expects post-marketing Covid study to cost up to $90M - Endpoints News

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax stock surges as HHS pulls mRNA vaccine funding, opening doors for alternative technologies - The Business Journals

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax outlook 2025 adjusted revenue $1 bln to $1.05 bln versus IBES estimate $1.02 bln - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification - Investing.com India

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax banks on vaccine supply partnerships to boost 2025 revenue - Reuters

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Shares Rise Following Avian Flu Vaccine Success​ - StocksToTrade

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax’s Vaccine Breakthrough Signals Optimism Amid Changing Market Dynamics - timothysykes.com

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax (NVAX) Boosts 2025 Revenue Outlook Amid Strategic Collab - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Earnings call transcript: Novavax Q2 2025 reports unexpected profit, stock surges - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

Can Novavax’s Innovation Fuel a Stock Rebound? - StocksToTrade

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Q2 2025 slides: Milestone revenue drives profit amid strategic shift - Investing.com Australia

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Q2 Earnings, Revenue Fall; Full-Year Adjusted Revenue Outlook Raised - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax (NVAX) Raises Revenue Forecast Amid Strong Vaccine Partn - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax (NVAX) Surpasses Earnings Expectations with Revenue Boos - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Earnings snapshot: Novavax tops Q2 estimates; raises full-year outlook - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax stock higher on Q2 beat, guidance (NVAX:NASDAQ) - Seeking Alpha

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax raises annual revenue forecast on vaccine supply partnerships - Reuters

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax lifts 2025 revenue outlook after FDA milestone payment By Investing.com - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax earnings beat by $0.68, revenue topped estimates - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Inc (NVAX) Q2 2025 Earnings: EPS of $0.62 Beats Estimate, Revenue Surges to $239 Million - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Reports Second Quarter 2025 Financial Results and Operat - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax beats quarterly revenue estimates on milestone payment - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $239.2M, vs. FactSet Est of $152.6M - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

Earnings Flash (NVAX) Novavax Posts Q2 Revenue $239.2M, vs. FactSet Est of $152.6M - MarketScreener

Aug 06, 2025
pulisher
Aug 06, 2025

NOVAVAX INC SEC 10-Q Report - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga

Aug 06, 2025
pulisher
Aug 05, 2025

Novavax Q2 2025 Earnings Preview - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

Novavax (NVAX) Prepares for Q2 Earnings Report Amid Earnings His - GuruFocus

Aug 05, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Novavax Inc. in the next 12 monthsCapitalize on strong market momentum - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Novavax Inc. company’s key revenue driversUnlock exclusive stock market forecasts - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Novavax Inc. stockCapitalize on market momentum for profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Novavax Inc. stock attracting strong analyst attentionGrow your wealth with proven stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Novavax Inc. stock overvalued or undervaluedSuperior investment outcomes - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Novavax, Inc.'s (NASDAQ:NVAX) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Novavax Inc. stock higher in 2025Free Capital Growth Strategies - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Published on: 2025-08-03 16:04:49 - Jammu Links News

Aug 03, 2025

Finanzdaten der Novavax Inc-Aktie (NVAX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Novavax Inc-Aktie (NVAX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Alton Gregg H
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
28,805
King Rachel K.
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
25,190
Rodgers Richard J
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
24,690
MOTT DAVID M
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
60,890
DOUGLAS RICHARD
Director
Jun 12 '25
Option Exercise
0.00
10,420
0
54,340
$78.39
price up icon 0.24%
$37.58
price up icon 1.54%
$109.55
price up icon 0.23%
$28.66
price up icon 2.10%
$111.66
price up icon 0.28%
biotechnology ONC
$288.18
price down icon 3.39%
Kapitalisierung:     |  Volumen (24h):